Stimulants for the control of hedonic appetite

The focus of this paper is treatment of obesity in relation to the management of hedonic appetite. Obesity is a complex condition which may be potentiated by excessive reward seeking in combination with executive functioning deficits that impair cognitive control of behaviour. Stimulant medications...

Full description

Bibliographic Details
Main Authors: Alison Sally Poulton, Emily Jane Hibbert, Bernard Linton Champion, Ralph Kay Heinrich Nanan
Format: Article
Language:English
Published: Frontiers Media S.A. 2016-04-01
Series:Frontiers in Pharmacology
Subjects:
Online Access:http://journal.frontiersin.org/Journal/10.3389/fphar.2016.00105/full
id doaj-db01d65a57d446d488eecc7a29e5208d
record_format Article
spelling doaj-db01d65a57d446d488eecc7a29e5208d2020-11-24T22:27:42ZengFrontiers Media S.A.Frontiers in Pharmacology1663-98122016-04-01710.3389/fphar.2016.00105180885Stimulants for the control of hedonic appetiteAlison Sally Poulton0Emily Jane Hibbert1Bernard Linton Champion2Ralph Kay Heinrich Nanan3The University of SydneyThe University of SydneyThe University of SydneyThe University of SydneyThe focus of this paper is treatment of obesity in relation to the management of hedonic appetite. Obesity is a complex condition which may be potentiated by excessive reward seeking in combination with executive functioning deficits that impair cognitive control of behaviour. Stimulant medications address both reward deficiency and enhance motivation, as well as suppressing appetite. They have long been recognised to be effective for treating obesity. However, stimulants can be abused for their euphoric effect. They induce euphoria via the same neural pathway that underlies their therapeutic effect in obesity. For this reason they have generally not been endorsed for use in obesity. Among the stimulants, only phentermine (either alone or in combination with topiramate) and bupropion (which has stimulant-like properties and is used in combination with naltrexone), are approved by the United States Food and Drug Administration (FDA) for obesity, although dexamphetamine and methylpenidate are approved and widely used for treating attention deficit hyperactivity disorder (ADHD) in adults and children. Experience gained over many years in the treatment of ADHD demonstrates that with careful dose titration, stimulants can be used safely. In obesity, improvement in mood and executive functioning could assist with the lifestyle changes necessary for weight control, acting synergistically with appetite suppression. The obesity crisis has reached the stage that strong consideration should be given to adequate utilisation of this effective and inexpensive class of drug.http://journal.frontiersin.org/Journal/10.3389/fphar.2016.00105/fullObesityPhentermineappetite suppressantsDexamphetamineReward deficiencyhedonic appetite
collection DOAJ
language English
format Article
sources DOAJ
author Alison Sally Poulton
Emily Jane Hibbert
Bernard Linton Champion
Ralph Kay Heinrich Nanan
spellingShingle Alison Sally Poulton
Emily Jane Hibbert
Bernard Linton Champion
Ralph Kay Heinrich Nanan
Stimulants for the control of hedonic appetite
Frontiers in Pharmacology
Obesity
Phentermine
appetite suppressants
Dexamphetamine
Reward deficiency
hedonic appetite
author_facet Alison Sally Poulton
Emily Jane Hibbert
Bernard Linton Champion
Ralph Kay Heinrich Nanan
author_sort Alison Sally Poulton
title Stimulants for the control of hedonic appetite
title_short Stimulants for the control of hedonic appetite
title_full Stimulants for the control of hedonic appetite
title_fullStr Stimulants for the control of hedonic appetite
title_full_unstemmed Stimulants for the control of hedonic appetite
title_sort stimulants for the control of hedonic appetite
publisher Frontiers Media S.A.
series Frontiers in Pharmacology
issn 1663-9812
publishDate 2016-04-01
description The focus of this paper is treatment of obesity in relation to the management of hedonic appetite. Obesity is a complex condition which may be potentiated by excessive reward seeking in combination with executive functioning deficits that impair cognitive control of behaviour. Stimulant medications address both reward deficiency and enhance motivation, as well as suppressing appetite. They have long been recognised to be effective for treating obesity. However, stimulants can be abused for their euphoric effect. They induce euphoria via the same neural pathway that underlies their therapeutic effect in obesity. For this reason they have generally not been endorsed for use in obesity. Among the stimulants, only phentermine (either alone or in combination with topiramate) and bupropion (which has stimulant-like properties and is used in combination with naltrexone), are approved by the United States Food and Drug Administration (FDA) for obesity, although dexamphetamine and methylpenidate are approved and widely used for treating attention deficit hyperactivity disorder (ADHD) in adults and children. Experience gained over many years in the treatment of ADHD demonstrates that with careful dose titration, stimulants can be used safely. In obesity, improvement in mood and executive functioning could assist with the lifestyle changes necessary for weight control, acting synergistically with appetite suppression. The obesity crisis has reached the stage that strong consideration should be given to adequate utilisation of this effective and inexpensive class of drug.
topic Obesity
Phentermine
appetite suppressants
Dexamphetamine
Reward deficiency
hedonic appetite
url http://journal.frontiersin.org/Journal/10.3389/fphar.2016.00105/full
work_keys_str_mv AT alisonsallypoulton stimulantsforthecontrolofhedonicappetite
AT emilyjanehibbert stimulantsforthecontrolofhedonicappetite
AT bernardlintonchampion stimulantsforthecontrolofhedonicappetite
AT ralphkayheinrichnanan stimulantsforthecontrolofhedonicappetite
_version_ 1725748837254955008